This book delves into the scientific foundations of mucosal vaccine platforms, discussing immunological mechanisms, novel adjuvants, and real-world development challenges. It serves as a valuable resource for professionals and students in life sciences, immunology, and pharmacology.
Researchers at the University of Graz and the University of California, San Diego have developed a novel method to determine omega positions of lipids in complex biological samples. This breakthrough enables the study of biological mechanisms in unprecedented detail, particularly for inflammation-related diseases.
The book examines antibiotic-induced reproductive toxicity, microbiome alterations, and emerging concerns around antibiotic resistance. It provides critical insights for clinicians, pharmacists, researchers, and students in reproductive medicine and pharmacology.
A comprehensive review in Current Molecular Pharmacology explores the mechanisms of hepatic ischemia-reperfusion injury (IRI) and emerging treatments. Effective strategies include antioxidant administration, surgical preconditioning, and herbal compounds with anti-inflammatory and antioxidant properties.
A University of Cincinnati researcher is investigating how excess sugar impacts cardiovascular structure and function in people with diabetes. The study focuses on a protein called GLUT1, which becomes overactive in diabetes, leading to harmful changes at the cellular level.
Current Molecular Pharmacology seeks talented young professionals for its editorial board. The journal focuses on cellular and molecular pharmacology advancements, genomics, proteomics, and drug action mechanisms.
Researchers from Tsinghua University Press have discovered three novel bianthrones with significant cytotoxic activity against tumor cell lines. The compounds were isolated using HSQC-based DeepSAT technology, and their mechanisms of action were investigated through network pharmacology and molecular docking.
A clinical trial found that women experience stronger subjective effects of acute alcohol intake, such as drunkenness and sedation, compared to men. The study adjusted doses to achieve identical blood alcohol concentrations for both sexes, revealing that women's effects were more intense.
A new study suggests Caligula was knowledgeable about medicine, particularly medicinal plants like hellebore, contrary to the traditional portrayal of him as a bloodthirsty tyrant. The Roman Empire's Antikyra spa town was renowned for its perceived efficacy in treating various ailments.
The American College of Chest Physicians (CHEST) has launched a critical care APP education and certification program, covering 11 topic areas including patient-centered care and pharmacology. The CCAPP Certification Exam is now available, with an August 5 deadline to apply for the 2025 exam.
The journal Current Pharmaceutical Analysis (CPA) has seen a significant increase in its impact factor, doubling from the previous year to 1.5. This achievement indicates a substantial boost in the average impact of each published paper, attracting more top-tier research findings.
Current Molecular Pharmacology's 2024 Impact Factor increased to 2.9, advancing to the Q2 zone in PHARMACOLOGY & PHARMACY. The journal has achieved notable recognition and influence in its field.
Dr. Nikolaos Koundouros has been awarded the 2025 Tri-Institutional Breakout Award for his research on how cells detect and respond to dietary nutrients, specifically omega-6 and omega-3 fatty acids, in relation to breast cancer development.
This study investigates the immunomodulatory effects of Ejiao on chronic obstructive pulmonary disease (COPD), focusing on its impact on inflammatory pathways and macrophages. Ejiao significantly improves lung function in COPD model mice, reduces inflammation, and modulates the ER/AKT/NF-κB pathway.
A study published in Nature reveals that cysteine depletion disrupts metabolic pathways, forcing cells to rapidly burn fat stores. The research also highlights the role of coenzyme A (CoA) in shaping metabolism and provides insights into potential future obesity solutions.
The study shows that Huo Xue Tong Luo capsule inhibits osteoclast formation and protects bone mass in ovariectomized mice. The PI3K-AKT signaling pathway is targeted to prevent bone loss induced by ovariectomy.
A UT Health San Antonio-led discovery could redefine drug discovery by turning IV medications into orally administered treatments for brain cancer, Alzheimer’s disease, and other complex conditions. The new strategy uses a protein receptor called CD36 to efficiently deliver large molecules into cells.
Qin-Zhu-Liang-Xue decoction has shown promising results in treating atopic dermatitis through the enhancement of glucocorticoid receptor alpha (GRα) expression. Clinical trials and animal experiments have demonstrated its efficacy, reducing inflammation and improving symptoms.
Research at the University of Arizona Health Sciences found that certain terpenes in Cannabis sativa are effective at relieving post-surgical and fibromyalgia pain in preclinical models. Terpenes have been shown to provide significant pain relief in mouse models, with geraniol providing the most significant level of pain relief.
Researchers found that melatonin improves mitochondrial function, reduces cellular stress, and prevents programmed cell death, promoting the conversion of glycolytic to oxidative fibers in muscle tissue. This change optimizes energy production and protects against muscle deterioration caused by obesity and type 2 diabetes.
The University of Arizona has approved a new Bachelor of Science in Medical Pharmacology and Toxicology degree to support the AZ Healthy Tomorrow initiative. The program explores the effects of chemicals on human health and prepares students for jobs in fields like poison control, medical courier, and sanitization compliance.
The Neuro-Oncology Translational Research Training Program aims to bridge laboratory discoveries and clinical applications in neuro-oncology, targeting glioblastoma and brain metastases. The program provides predoctoral and postdoctoral trainees with cutting-edge lab experience and mentorship across multiple disciplines.
A recent study published in Communications Biology reveals that the Sudan virus binds to human cells through a specific protein called NPC1, which enables it to attach with nine times greater affinity than Ebola. This discovery may contribute to the high fatality rate of the Sudan virus.
The BfR is seeking experts from biochemistry, medicine, toxicology, pharmacology, statistics, and sociology to advise on risk assessment issues. The selected scientists will contribute their expertise to the commissions for a four-year term.
The January issue of the American Journal of Psychiatry explores the use of psychedelic medications in psychiatry, addressing basic pharmacology, clinical efficacy, and public health considerations. The series of articles aims to provide sufficient evidence for therapeutic strategies utilizing psychedelic drugs.
Scientists at Baylor College of Medicine have identified liquid-like condensates as replication hubs for human norovirus. These biomolecular structures are dynamic and can merge or divide, exchanging materials with their surroundings.
Researchers developed SMART, a new software package simulating complex cell-signaling networks with realistic 3D shapes and interactions. This tool helps advance understanding of cellular behavior and drives development of new treatments for human diseases.
Researchers at Case Western Reserve University have discovered a potential target for treating drug-resistant malaria, PfNCR1, a cholesterol-managing protein. A compound known as MMV009108 can physically block the transporter, preventing it from doing its job and potentially killing the parasite.
Christopher Kassotis, a Wayne State University assistant professor of pharmacology, has been recognized for his outstanding work on endocrine disruption research. His research focuses on identifying and characterizing environmental chemicals that impact human and animal health.
A UT Health San Antonio study found that brain volume changes correlate with social behavior differences in psychiatric conditions such as autism spectrum disorder and schizophrenia. Tbx1 deficiency was associated with decreased brain volume in the amygdala and surrounding cortical regions, affecting desire for social interaction.
A new study found a 29% increase in risk for developing dyslipidemia due to COVID-19, with seniors and people with type 2 diabetes being most affected. The research suggests that tackling dyslipidemia can reduce the risk of cardiovascular disease in those who have had COVID.
The study identified 97 potential therapeutic targets for SFJD, with 27 key targets involved in antiviral, anti-inflammatory, and immune regulation effects. Molecular docking results showed strong interactions between core active ingredients and these targets.
Researchers at NYU Langone Health develop antibodies that selectively target mutant HER2 cancer protein without harming healthy cells. The new treatment, a bispecific T cell engager, shows promise in reducing tumor growth with minimal side effects.
Researchers from University of Queensland discovered a toxin in ant venom that causes extreme pain by hyperstimulating sodium channels. The study uses electrophysiology and pharmacology to understand the mechanism, which may also apply to other insects like wasps and bees.
Researchers aim to develop small molecule drugs to target neuroinflammation in the brain, which contributes to cognitive decline. The goal is to slow or even cure Alzheimer's disease, offering a potential game-changer for the therapeutic landscape.
Researchers explore immune activation and tumor-promoting transcription factor FOXM1's role in CDK4/6-MEK resistance. They suggest targeting the oncogenic network of CDK4/6, MEK, PD-L1, and FOXM1 as future treatment options for MPNST patients.
A new study in ACS Pharmacology & Translational Science investigates the molecular mechanisms behind Efavirenz's negative effects on brain function. The research reveals that the drug alters lipid metabolism and downregulates certain enzymes, which could lead to the development of new drugs to block its negative activity.
Biomedical engineers at the University of Rochester have developed a novel technique using ultrasound waves to organize endothelial cells into patterns that promote the growth of new vessel networks. The team aims to treat ischemic injuries caused by damaged tissue in reconstructive and plastic surgeries.
Researchers analyzed collision-type mixed ductal-lobular breast cancers and found that IDC and ILC regions had distinct gene expression profiles. The study reveals tremendous variation within this already highly variable disease, highlighting the need for personalized treatments.
Researchers from Drexel University have identified two compounds, AD-5584 and AD-8007, that selectively kill cancer cells and block tumor growth by targeting a key metabolic enzyme in cancer cells. These findings show early success in shrinking breast cancer tumors in brain metastases and offer hope for more effective therapies.
Researchers identified a viable path to developing a novel therapy that would make opioids more effective and safer as a treatment for chronic pain. The study found that selective Hsp90 inhibitors amplified the pain-relieving effects of morphine, reducing tolerance and side effects.
Researchers at the University of Würzburg have discovered a natural substance that can inhibit vitamin B6 degradation, increasing its levels in nerve cells involved in learning and memory processes. This compound, 7,8-Dihydroxyflavone, has been linked to improved spatial learning and memory capacity in mice.
A recent study published in BRAIN found that males and females differ in their experience of pain due to functional sex differences in nociceptors. The findings support the implementation of a precision medicine-based approach considering patient sex as fundamental to treatment choices.
Researchers will study FSH's role in obesity, osteoporosis, and Alzheimer's disease. The grant aims to develop new treatments for these conditions and improve quality of life for older adults worldwide.
The article reviews research progress on the biosynthesis, metabolic engineering, and pharmacology of bioactive compounds from the Lonicera genus. Key findings include anti-inflammatory, antibacterial, antioxidant stress, and liver protection effects of Lonicera plants.
A mouse study found that heart failure with preserved ejection fraction (HFpEF) differs between male and female mice, with females exhibiting altered heart filament proteins and males showing slowed calcium removal. This may lead to different treatment strategies for women compared to men with HFpEF.
Researchers found that five cannabis terpenes reduced chronic neuropathic pain levels comparable to morphine. The combination of terpenes and morphine enhanced pain relief without negative side effects. Terpenes offer an alternative to opioids for pain management with a better side effect profile.
The study reveals that FLVCR1 and FLVCR2 transport choline and ethanolamine across cellular membranes, supporting cell growth and stability. This discovery contributes to understanding rare diseases and developing new therapies for patients suffering from severe neurological and muscular disorders.
A team of researchers at the University of Houston has identified AKAP12 as a promising target for treating heart failure through precision pharmacology. Increased levels of AKAP12 in cardiac myocytes accelerate cardiac dysfunction, but inhibiting PDE8A can reverse this effect and improve contractility.
Researchers at University of Cologne discover Cnicin, a plant-based compound that significantly accelerates axon growth in animal models and human cells. This breakthrough has the potential to treat paralysis and neuropathy by enabling nerves to regenerate more quickly.
This study investigates Schisanhenol's potential to treat cytokine storm by inhibiting inflammatory responses and alleviating acute lung injury. Network pharmacology analysis reveals multiple mechanisms of action.
A new study found that many newly approved EU oncology drugs lack proof of added benefit, with over half recovering R&D costs within three years. This challenges the industry's claim that high drug prices are necessary to offset R&D expenses.
Scientists have discovered that inhibiting the Mdm2 protein can prevent the destruction of synapses and dendritic spines in Alzheimer's disease. This breakthrough could lead to a new approach for treating the disease, which may be more effective than current anti-amyloid therapies.
A McGill-led study found that fathers exposed to environmental toxins like DDT may produce sperm with health consequences for their children, increasing the risk of birth defects and diseases. The study's findings highlight the importance of considering fathers in discussions about child health and development.
Researchers at Germans Trias i Pujol Research Institute have identified a combination of drugs that could change the treatment of patients with prostate cancer resistant to docetaxel. The study proposes a new treatment based on a combination of kinase inhibitors in patients who inevitably stop responding to docetaxel.
A study in rats found that excessive adolescent stress alters genes associated with energy metabolism, leading to behavioral problems and psychiatric disorders in adulthood. The prefrontal cortex's response to stress was also affected, suggesting a link between mitochondrial function and emotional regulation.
A Mount Sinai study found that human beliefs about nicotine can modulate brain activities in a way comparable to pharmacology, with potential implications for addiction treatment. The study used fMRI to explore the relationship between subjective beliefs and biological substrates in the human brain.
Researchers at Purdue University have developed a novel cancer immunotherapy compound that targets the enzyme TC-PTP, found in both cancer cells and T cells. Deleting this enzyme promotes antigen presentation, alerting the immune system to tumor cells, while stimulating T-cell activation enhances their ability to fight and destroy tumors.
Researchers found that metformin restores mitochondrial activity and prevents cancer progression in mice and human prostate cells, particularly those with low NKX3.1 levels. The study suggests metformin could be used to prevent further progression of cancer in patients under active surveillance with low-NKX3.1 tumors.
Researchers at the University of Arizona Health Sciences will train the next generation of translational scientists in Alzheimer's disease research through a $1.4 million grant. The program aims to develop highly trained, cross-disciplinary researchers to address the complex challenges of this devastating neurodegenerative disorder.